Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma"
Document Type
Article
Publication Title
Gynecologic oncology
First Page
334
DOI
10.1016/j.ygyno.2023.01.029
Publication Date
3-1-2023
Recommended Citation
Harold, Justin; Bellone, Stefania; Manavell, Diego D.; Mutlu, Levent; McNamara, Blair; Hartwich, Tobias Max; Zipponi, Margherita; Yang-Hartwich, Yang; Demirkiran, Cem; Verzosa, Miguel Skyler; Choi, Jungmin; Dong, Weilai; Buza, Natalia; Hui, Pei; Altwerger, Gary; Huang, Gloria S.; Andikyan, Vaagn; Clark, Mitchell; Ratner, Elena; Azodi, Masoud; Schwartz, Peter E.; and Santin, Alessandro D., "Corrigendum to "Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma"" (2023). Obstetrics and Gynecology. 103.
https://scholar.bridgeporthospital.org/obgyn/103
Identifier
36906375 (pubmed); NIHMS1883824 (mid); PMC10266020 (pmc); 10.1016/j.ygyno.2023.01.029 (doi); S0090-8258(23)00029-X (pii)